Synonyms: CD3E, IL3RA Clone No.:Mel-14
Anti-mouse L-Selectin (CD62L)-InVivo reacts with mouse CD62L also known as L-selectin and MEL-14. CD62L is a 76 kDa glycoprotein and a member of the selectin family.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Molecular Weight | 150 kDa |
|---|---|
| Clone | Mel-14 |
| Isotype | Rat IgG2a, κ |
| Application | in vivo CD62L neutralization. |
| Source | CHO |
| Purification | Protein G |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.0. Contains no stabilizers or preservatives |
| Murine Pathogen Screening Panel | all targets tested yielded Negative Results: Theiler’s Murine Encephalomyelitis Virus, Ectromelia (Mousepox) Virus, Hantavirus, Polyomavirus, Sendai Virus, Mycoplasma pulmonis, Pneumonia Virus of Mice, K Virus, Mouse Parvovirus, Mouse Hepatitis Virus, Mouse Norovirus, Mouse Minute Virus, Mouse Cytomegalovirus, Mouse Adenovirus, Lactate Dehydrogenase-Elevating Virus, Reovirus Panel, Lymphocytic Choriomeningitis Virus, Mouse Rotavirus. |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT06034535 | RECRUITING | Hematopoietic Organs; Disorder | Hong Kong Children's Hospital | 2023-09-01 | PHASE2 | |
| NCT03836690 | UNKNOWN | Lymphoma; Leukemia; Myeloma; Myelodysplastic Syndromes; Severe Aplastic Anemia; Primary Immune Deficiency; Graft Vs Host Disease | University College, London | 2019-10-21 | PHASE1 | |
| NCT02062359 | TERMINATED | Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine | Metastatic Cancer; Metastatic Melanoma | National Cancer Institute (NCI) | 2014-02 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2025-09-15)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.